Format

Send to

Choose Destination
J Cent Nerv Syst Dis. 2011 Sep 14;3:199-207. doi: 10.4137/JCNSD.S6371. Print 2011.

Safety and efficacy of vigabatrin for the treatment of infantile spasms.

Author information

1
Creighton University School of Pharmacy, Omaha, Nebraska, 68178, USA.

Abstract

In 2009, vigabatrin became the first FDA approved medication for the treatment of infantile spasms in the United States. There are few well-designed prospective studies comparing the drug to placebo or other modalities used in the treatment of infantile spasms. The available data have demonstrated that vigabatrin is efficacious in the treatment of infantile spasms regardless of underlying etiology, but that it is particularly beneficial in patients with a diagnosis of tuberous sclerosis. Adrenocorticotropic hormone (ACTH), the only other medication with robust efficacy data, has been used as first line therapy for infantile spasms associated with other etiologies, and in general controls spasms sooner than vigabatrin, though relapse is common with both therapies. Vigabatrin is generally well tolerated. However, use has been associated with permanent loss of peripheral vision in some patients. In children with tuberous sclerosis, vigabatrin should be considered as initial therapy for infantile spasms. It is a viable alternative for patients with suboptimal response, contraindications or intolerance to ACTH.

KEYWORDS:

ACTH; hypsarrhythmia; infantile spasms; tuberous sclerosis; vigabatrin

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center